Information Provided By:
Fly News Breaks for November 13, 2019
Nov 13, 2019 | 16:11 EDT
Roth Capital analyst Zegbeh Jallah initiated coverage of Harpoon Therapeutics with a Buy rating and $25 price target. The analyst likes Harpoon's modular, tri-specific T-cell targeting platform and the company's clinical strategy focusing on biomarker-selected patients that could allow for a faster path to approval. Harpoon has a next-generation tri-specific platform optimized for efficient tumor penetration, limited toxicity, and more convenient dosing, Jallah tells investors in a research note.
News For HARP From the Last 2 Days
There are no results for your query HARP